Category

• Business1
• Pipeline1

Organizations

• Bausch + Lomb66
• Eyes On Eyecare47
• Alcon, Inc.44
• American Optometric Association35
• Harrow29
• Glaukos26
• Regeneron23
• Topcon Healthcare23
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• Glaucoma2
• FDA1
• Ocular Hypertension1
• Acquisitions1
• Eye Drop Solution1
• Eye Drops1
• Glaucoma Management1
• Merger1

• Organizations: Ocuvex Therapeutics✕

Clear all

Pipeline

Ocuvex resubmits FDA CRL for brimonidine tartrate 0.35% NDA

Shared by partner SPARC, update follows 2+ years after the 2022 submission of investigational OAG and OHT eye drop was rejected in July 2023.

Business

Ocuvex Therapeutics to merge with Visiox Pharmaceuticals

Deal includes Visiox’s OMLONTI, indicated to treat glaucoma and ocular hypertension.